Shanmuga Hospital Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Shanmuga Hospital Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹54
Per ShareLot Size
2000 Shares
Minimum Investment
₹1,08,000
Issue Size
₹20.62 Cr
Face Value
₹10
Per ShareIPO Type
Fixed Price - SME
Retail Quota
50.03%
QIB Quota
0%
NII Quota
49.97%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Shanmuga Hospital Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
99.23%
Promoter Holding (Post-Issue)
71.4%
Issue Type
Fixed Price - SME
ISIN
INE0TD301017
About the Company
Shanmuga Hospital Limited, a Multispecialty Hospital, is strategically established in Salem, Tamil Nadu. Equipped with advanced healthcare technology and having 151 bed capacity, it addresses the community's medical needs, serving patients from nearby regions. Accredited by the National Accreditation Board for Hospitals and Healthcare ("NABH Accredited") and National Accreditation Board for Testing and Calibration Laboratories ("NABL Accredited"), our hospital is committed to high-quality healthcare services, including prevention, treatment, and rehabilitation.
Industry Overview
The Indian Healthcare industry continued its healthy growth in 2023 and reached a value of US$ 372 billion driven by both the private sector and the government. As of 2024, the Indian healthcare sector is one of India's largest employers as it employs a total of 7.5 million people. Progress in telemedicine, virtual assistants, and data analytics is expected to create 2.7-3.5 million new tech jobs. India's public expenditure on healthcare touched 2.1 % of GDP in FY23 and 2.2% in FY22, against 1.6% in FY21, as per the Economic Survey 2022-23. India's hospital market was valued at US$ 98.98 billion in 2023, projected to grow at a CAGR of 8.0% from 2024 to 2032, reaching an estimated value of US$ 193.59 billion by 2032. In FY24 (Till February 2024), premiums underwritten by health insurance companies grew to Rs. 2,63,082 crore (US$ 31.84 billion). The health segment has a 33.33% share in the total gross written premiums earned in the country. Indian medical tourism market was valued at US$ 7.69 billion in 2024 and is expected to reach US$ 14.31 billion by 2029. According to India Tourism Statistics, around 634,561 foreign tourists came for medical treatment in India in 2023, which was nearly 6.87% of the total international tourists who visited the nation. With US$ 5-6 billion size of medical value travel (MVT) and 500000 International patients annually, India is among the global leader destinations for international patients seeking advanced treatment. The e-health market size is estimated to reach US$ 10.6 billion by 2025. As per information provided to the Lok Sabha by the Minister of Health & Family Welfare, Dr. Bharati Pravin Pawar, the doctor population ratio in the country is 1:854, assuming 80% availability of 12.68 lakh registered allopathic doctors and 5.65 lakh AYUSH doctors.
Company History
Our company was originally incorporated as a Private Limited Company under the name "Shanmuga Hospital Private Limited" on June 26, 2020, in accordance with the Companies Act, 2013. We received a fresh certificate of incorporation, bearing the corporate identification number U85110TZ2020PTC033974, from the Registrar of Companies, Central Registration Centre. Subsequently, our company converted into a public limited company, resulting in a name change to "Shanmuga Hospital Limited." This alteration was formally recorded in a new Certificate of Incorporation dated June 06, 2024, with the Corporate Identification Number U85110TZ2020PLC033974, issued by the Registrar of Companies, Central Processing Centre. s
Growth Strategy
- Ultra-Modern Medicinal Practices.
- Prime Location of our Hospital.
- Team of Medical Practitioners.
- Clinical excellence and affordable health care.
- Improve Operational efficiencies.
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of up to 38,18,000 equity shares of face value of Rs.10/- each ("equity shares") of Shanmuga Hospital Limited (the "company" or the "issuer") for cash at a price of Rs.54/- per equity share, including a share premium of Rs.44/- per equity share (the "issue price"), aggregating to Rs. 20.61 crores ("the issue"), of which 1,92,000 equity shares of face value of Rs.10/- each for cash at a price of Rs.54/- per equity share, aggregating to Rs. 1.03 crores will be reserved for subscriptions by the market maker to the issue (the "market maker reservation portion"). The issue less market maker reservation portion i.e. issue of 36,26,000 equity shares of face value of Rs.10/- each for cash at a price of Rs.54/- per equity share, aggregating to Rs. 19.58 crores is here in after referred to as the "net issue". the issue and the net issue will constitute 28.05% and 26.64% respectively of the post issue paidup equity share capital of the company. The face value of the equity share is Rs.10/- each and the issue price is Rs.54/- each i.e., 5.4 times of the face value of the equity shares. The minimum lot size is 2,000 equity shares.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Established and proven track record.
- Leveraging the experience of our Promoters.
- Experienced management team and a motivated and efficient work force.
- Cordial relations with our customers.
- Quality Assurance & Control.
- The Company, Directors, Promoters and Group Companies are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on its business, results of operations and financial conditions.
- The Company has limited operating history, and therefore investors may not be able to assess its prospects on the basis of historical results.
- The company is highly dependent on its healthcare professionals, including doctors, nurses that the company engage on a consultancy basis, and its business and financial results could be impacted if the company is not able to attract and retain such healthcare professionals.
- The Company is yet to place orders for medical equipment proposed to be installed at its hospital. Any delay in placing orders or procurement of such equipment may delay the schedule of implementation and possibly increase the cost of commencing operations.
- The company generates certain revenues from the arrangements with government sponsored health schemes, any adverse change in these regulations/government policies related to such schemes may adversely affect its business, results of operations, cash flows and prospects.